Licensing opportunity from NIH: BRCA1 mutants for modulating cellular response to DNA damage Feb. 14, 2001
Antiangiogenic tyrosine kinase inhibitors disclosed by Celltech scientists in recent patent Feb. 13, 2001
RSS